There are a number of clinical trials currently underway to investigate the use of medical cannabis to treat PTSD. These trials are being conducted at universities and research institutions around the world.

One of the largest and most well-designed clinical trials of medical cannabis for PTSD is the Cannabinoids for the Treatment of PTSD (CPT) study. This trial is being conducted by the National Institute on Drug Abuse (NIDA) and is expected to be completed in 2025.

The CPT study is a randomized, double-blind, placebo-controlled trial. This means that participants are randomly assigned to receive either medical cannabis or a placebo, and neither the participants nor the researchers know who is receiving which treatment. This type of study design is considered to be the gold standard for clinical research.

The CPT study is evaluating the safety and efficacy of two different types of medical cannabis for PTSD: nabiximols (Sativex) and cannabidiol (CBD). Nabiximols is a spray that contains both THC and CBD, while CBD is a non-psychoactive compound in cannabis that has been shown to have anti-anxiety and anti-inflammatory effects.

The CPT study is recruiting veterans and civilians with PTSD. The study participants will receive either medical cannabis or a placebo for 12 weeks. The researchers will assess the participants’ PTSD symptoms, sleep quality, and overall quality of life at the start of the study, at the end of the 12-week treatment period, and at 6-month and 12-month follow-up visits.

The results of the CPT study are highly anticipated. If the study finds that medical cannabis is safe and effective for PTSD, it could lead to new treatment options for this debilitating condition.

In addition to the CPT study, there are a number of other clinical trials underway to investigate the use of medical cannabis for PTSD. These trials are evaluating different types of medical cannabis, different treatment regimens, and different patient populations.

The results of these clinical trials will help to shed light on the potential benefits and risks of using medical cannabis to treat PTSD.

There are indeed a number of clinical trials currently underway to investigate the use of medical cannabis to treat PTSD. One of the largest and most well-designed clinical trials of medical cannabis for PTSD is the Cannabinoids for the Treatment of PTSD (CPT) study, which is being conducted by the National Institute on Drug Abuse (NIDA) and is expected to be completed in 2025¹. The CPT study is a randomized, double-blind, placebo-controlled trial, which means that participants are randomly assigned to receive either medical cannabis or a placebo, and neither the participants nor the researchers know who is receiving which treatment. This type of study design is considered to be the gold standard for clinical research¹.

The CPT study is evaluating the safety and efficacy of two different types of medical cannabis for PTSD: nabiximols (Sativex) and cannabidiol (CBD)¹. Nabiximols is a spray that contains both THC and CBD, while CBD is a non-psychoactive compound in cannabis that has been shown to have anti-anxiety and anti-inflammatory effects¹.

The CPT study is recruiting veterans and civilians with PTSD. The study participants will receive either medical cannabis or a placebo for 12 weeks. The researchers will assess the participants’ PTSD symptoms, sleep quality, and overall quality of life at the start of the study, at the end of the 12-week treatment period, and at 6-month and 12-month follow-up visits¹.

The results of the CPT study are highly anticipated. If the study finds that medical cannabis is safe and effective for PTSD, it could lead to new treatment options for this debilitating condition¹.

In addition to the CPT study, there are a number of other clinical trials underway to investigate the use of medical cannabis for PTSD. These trials are evaluating different types of medical cannabis, different treatment regimens, and different patient populations¹²³.

Learn more:

1. trialsjournal.biomedcentral.com2. ptsd.va.gov3. link.springer.com4. bmcpsychiatry.biomedcentral.com